Safety and immunogenicity of a hexavalent vaccine administered at 2, 4 and 6 months of age with or without a heptavalent pneumococcal conjugate vaccine: A randomized, open-label study

Pediatric Infectious Disease Journal

Volumn 32, Issue 1, 2013, Pages 54-61

  Tapiéro, Bruce ^a   Halperin, Scott A ^b   Dionne, Mark ^c   Meekison, William ^d   Diaz Mitoma, Francisco ^e   Zickler, Paul ^f   Rubin, Earl ^g   Embree, Joanne ^h   Bhuyan, Prakash ⁱ   Lee, Andrew W ⁱ   Li, Minran ^j   Tomovici, Antigona ^j  

^a UNIVERSITY OF MONTREAL   (Canada)

^b IWK HEALTH CENTRE   (Canada)

^c LAVAL UNIVERSITY   (Canada)

^d Westcoast Clinical Research   (Canada)

^e CHILDREN S HOSPITAL OF EASTERN ONTARIO   (Canada)

^f TASC Research   (Canada)

^g MONTREAL CHILDREN S HOSPITAL   (Canada)

^h UNIVERSITY OF MANITOBA   (Canada)

ⁱ MERCK RESEARCH LABORATORIES   (United States)

^j Sanofi Pasteur Limited   (Canada)

more..

Author keywords

DTaP5 IPV Hib HepB; hexavalent vaccine; immunogenicity; infants; safety

Indexed keywords

DIPHTHERIA ANTIBODY; DIPHTHERIA PERTUSSIS POLIOMYELITIS TETANUS HAEMOPHILUS INFLUENZAE TYPE B HEPATITIS B VACCINE; DIPHTHERIA PERTUSSIS POLIOMYELITIS TETANUS HAEMOPHILUS INFLUENZAE TYPE B VACCINE; DIPHTHERIA TOXOID; HEMAGGLUTININ; HEPATITIS B SURFACE ANTIGEN; HEPTAVALENT PNEUMOCOCCAL CONJUGATE VACCINE; PERTACTIN; PNEUMOCOCCUS VACCINE; RECOMBINANT HEPATITIS B VACCINE; TETANUS TOXOID; UNCLASSIFIED DRUG; VIRUS ANTIGEN;

ACTIVE IMMUNIZATION; ANTIBODY RESPONSE; ANTIBODY TITER; APPETITE DISORDER; ARTICLE; CONTROLLED STUDY; CRYING; DROWSINESS; DRUG SAFETY; FEVER; GEOMETRY; GROUPS BY AGE; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; INFANT; INJECTION SITE ERYTHEMA; INJECTION SITE REACTION; INJECTION SITE SWELLING; IRRITABILITY; NORMAL HUMAN; OUTCOME ASSESSMENT; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEROCONVERSION; SIDE EFFECT; VOMITING;

ANTIBODIES, BACTERIAL; ANTIBODIES, VIRAL; ANTIGENS, BACTERIAL; ANTIGENS, VIRAL; DIPHTHERIA-TETANUS-PERTUSSIS VACCINE; FEMALE; HAEMOPHILUS VACCINES; HEPATITIS B VACCINES; HUMANS; INFANT; INFANT, NEWBORN; MALE; PNEUMOCOCCAL VACCINES; POLIOVIRUS VACCINE, INACTIVATED; VACCINES, COMBINED;

EID: 84871788521     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0b013e3182717edf     Document Type: Article

References (37)

1. National Center for Immunization and Respiratory Diseases. General recommendations on immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2011;60:1-64.
2. Szilagyi PG, Rodewald LE, Humiston SG, et al. Immunization practices of pediatricians and family physicians in the United States. Pediatrics. 1994;94(4, pt 1):517-523. (Pubitemid 24295034)
3. Askew GL, Finelli L, Lutz J, et al. Beliefs and practices regarding childhood vaccination among urban pediatric providers in New Jersey. Pediatrics. 1995;96(5, pt 1):889-892.
4. Woodin KA, Rodewald LE, Humiston SG, et al. Physician and parent opinions. Are children becoming pincushions from immunizations? Arch Pediatr Adolesc Med. 1995;149:845-849.
5. Zimmerman RK, Bradford BJ, Janosky JE, et al. Barriers to measles and pertussis immunization: the knowledge and attitudes of Pennsylvania primary care physicians. Am J Prev Med. 1997;13:89-97. (Pubitemid 27150500)
6. Zimmerman RK, Schlesselman JJ, Mieczkowski TA, et al. Physician concerns about vaccine adverse effects and potential litigation. Arch Pediatr Adolesc Med. 1998;152:12-19. (Pubitemid 28098934)
7. Meyerhoff AS, Jacobs RJ. Do too many shots due lead to missed vaccination opportunities? Does it matter? Prev Med. 2005;41:540-544. (Pubitemid 40732369)
8. Koslap-Petraco MB, Judelsohn RG. Societal impact of combination vaccines: experiences of physicians, nurses, and parents. J Pediatr Health Care. 2008;22:300-309.
9. Koslap-Petraco MB, Parsons T. Communicating the benefits of combination vaccines to parents and health care providers. J Pediatr Health Care. 2003;17:53-57. (Pubitemid 36890661)
10. Decker MD, Edwards KM. Haemophilus influenzae type b vaccines: history, choice and comparisons. Pediatr Infect Dis J. 1998;17(suppl 9):S113-S116. (Pubitemid 28460552)
11. Happe LE, Lunacsek OE, Marshall GS, et al. Combination vaccine use and vaccination quality in a managed care population. Am J Manag Care. 2007;13:506-512. (Pubitemid 47404427)
12. Kalies H, Grote V, Verstraeten T, et al. The use of combination vaccines has improved timeliness of vaccination in children. Pediatr Infect Dis J. 2006;25:507-512. (Pubitemid 43863360)
13. Marshall GS, Happe LE, Lunacsek OE, et al. Use of combination vaccines is associated with improved coverage rates. Pediatr Infect Dis J. 2007;26:496-500. (Pubitemid 46847310)
14. Reis EC, Roth EK, Syphan JL, et al. Effective pain reduction for multiple immunization injections in young infants. Arch Pediatr Adolesc Med. 2003;157:1115-1120. (Pubitemid 37433178)
15. Dodd D. Benefits of combination vaccines: effective vaccination on a simplified schedule. Am J Manag Care. 2003;9(suppl 1):S6-S12. (Pubitemid 36187460)
16. Mullany L. Considerations for implementing a new combination vaccine into managed care. Am J Manag Care. 2003;9(suppl 1):S23-S29. (Pubitemid 36192809)
17. Advisory Committee on Immunization Practices (ACIP), the American Academy of Pediatrics (AAP), and the American Academy of Family Physicians (AAFP).Combination vaccines for childhood immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP), the American Academy of Pediatrics (AAP), and the American Academy of Family Physicians (AAFP). Pediatrics. 1999;103:1064-1077.
18. Insel RA. Potential alterations in immunogenicity by combining or simultaneously administering vaccine components. Ann N Y Acad Sci. 1995;754:35-47.
19. Diaz-Mitoma F, Halperin SA, Tapiero B, et al. Safety and immunogenicity of three different formulations of a liquid hexavalent diphtheria-tetanus- acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccine at 2, 4, 6 and 12-14 months of age. Vaccine. 2011;29:1324-1331.
20. Halperin SA, Tapiero B, Diaz-Mitoma F, et al. Safety and immunogenicity of a hexavalent diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccine at 2, 3, 4, and 12-14 months of age. Vaccine. 2009;27:2540-2547.
21. Efstratiou A, Maple PAC. Manual for the Laboratory Diagnosis of Diphtheria. Copenhagen, Denmark: Expanded Programme on Immunization, World Health Organization Regional Office for Europe (ICP/EPI/038C); 1994.
22. Halperin SA, Langley JM, Hesley TM, et al. Safety and immunogenicity of two formulations of a hexavalent diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae conjugate-hepatitis B vaccine in 15 to 18-month-old children. Hum Vaccin. 2005;1:245-250.
23. Eskola J, Ward J, Dagan R, et al. Combined vaccination of Haemophilus influenzae type b conjugate and diphtheria-tetanus-pertussis containing acellular pertussis. Lancet. 1999;354:2063-2068.
24. Szmuness W, Stevens CE, Zang EA, et al. A controlled clinical trial of the efficacy of the hepatitis B vaccine (Heptavax B): a final report. Hepatology. 1981;1:377-385. (Pubitemid 12218155)
25. Coutinho RA, Lelie N, Albrecht-Van Lent P, et al. Efficacy of a heat inactivated hepatitis B vaccine in male homosexuals: outcome of a placebo controlled double blind trial. Br Med J (Clin Res Ed). 1983;286:1305-1308. (Pubitemid 13119878)
26. Ortega-Barrìa E, Kanra G, Leroux G, et al.; DTPw-HBV/Hib 2.5 study group. The immunogenicity and reactogenicity of DTPw-HBV/Hib 2.5 combination vaccine: results from four phase III multicenter trials across three continents. Vaccine. 2007;25:8432-8440. (Pubitemid 350137598)
27. Greenberg DP, Wong VK, Partridge S, et al. Immunogenicity of a Haemophilus influenzae type b-tetanus toxoid conjugate vaccine when mixed with a diphtheria-tetanus-acellular pertussis-hepatitis B combination vaccine. Pediatr Infect Dis J. 2000;19:1135-1140. (Pubitemid 32003355)
28. Poland GA. Acellular pertussis vaccines: new vaccines for an old disease. Lancet. 1996;347:209-210. (Pubitemid 26035241)
29. Cherry JD, Gornbein J, Heininger U, et al. A search for serologic correlates of immunity to Bordetella pertussis cough illnesses. Vaccine. 1998;16:1901-1906. (Pubitemid 28473933)
30. Storsaeter J, Hallander HO, Gustafsson L, et al. Levels of anti-pertussis antibodies related to protection after household exposure to Bordetella pertussis. Vaccine. 1998;16:1907-1916. (Pubitemid 28473934)
31. Olivier C, Belohradsky BH, Stojanov S, et al. Immunogenicity, reactogenicity, and safety of a seven-valent pneumococcal conjugate vaccine (PCV7) concurrently administered with a fully liquid DTPa-IPV-HBV-Hib combination vaccine in healthy infants. Vaccine. 2008;26:3142-3152.
32. Tichmann-Schumann I, Soemantri P, Behre U, et al. Immunogenicity and reactogenicity of four doses of diphtheria-tetanus-three-component acellular pertussis-hepatitis B-inactivated polio virus-Haemophilus influenzae type b vaccine coadministered with 7-valent pneumococcal conjugate Vaccine. Pediatr Infect Dis J. 2005;24:70-77. (Pubitemid 40353319)
33. Schmitt HJ, Faber J, Lorenz I, et al. The safety, reactogenicity and immunogenicity of a 7-valent pneumococcal conjugate vaccine (7VPnC) concurrently administered with a combination DTaP-IPV-Hib vaccine. Vaccine. 2003;21:3653-3662. (Pubitemid 37338190)
34. Knuf M, Habermehl P, Cimino C, et al. Immunogenicity, reactogenicity and safety of a 7-valent pneumococcal conjugate vaccine (PCV7) concurrently administered with a DTPa-HBV-IPV/Hib combination vaccine in healthy infants. Vaccine. 2006;24:4727-4736. (Pubitemid 43776787)
35. Black S, Shinefield H, Fireman B, et al. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group. Pediatr Infect Dis J. 2000;19:187-195. (Pubitemid 30167436)
36. Dagan R, Poolman J, Siegrist CA. Glycoconjugate vaccines and immune interference: A review. Vaccine. 2010;28:5513-5523.
37. Knuf M, Kowalzik F, Kieninger D. Comparative effects of carrier proteins on vaccine-induced immune response. Vaccine. 2011;29:4881-4890.